

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application:

Listing of Claims:

1. (withdrawn) A pharmaceutical composition comprising a caspase inhibitor and/or a compound of the formula R-Lys-X and at least one pharmaceutically acceptable carrier, polymer matrix, solvent and/or diluents.
2. (withdrawn – previously presented) The pharmaceutical composition according to claim 1, wherein the caspase inhibitor is selected from the group consisting of benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone, Ile-Glu-Thr-Asp-fluoromethyl ketone (SEQ ID NO: 66), t-butoxycarbonyl-Asp(OCH₃)--CH₂F, boc-aspartyl(OMe)-fluoromethylketone (BAF) and BOC-Asp-FMK (BD), BD-fmk, Z-FA-fmk, z-VAD, z-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk), IAP, benzyloxycarbonyl-Val-Ala-Asp(OCH₃)--CH₂-fluoromethyl ketone, benzyloxycarbonyl-Ile-Glu(OCH₃)-Thr-Asp(OCH₃)--CH₂-fluoromethyl ketone (SEQ ID NO: 66), Z-AAD-fmk, DEVD (SEQ ID NO: 1), Ac-DEVD-CHO (SEQ ID NO: 67), Z-Asp-CH₂-DCB, acetyl-Asp-Glu-Val-Asp-fluoromethyl-ketone (Ac-DEVD-FMK) (SEQ ID NO: 68), YVAD (SEQ ID NO: 2), acetyl-Tyr-Val-Ala-Asp-chloromethyl-ketone (Ac-YVAD-CMK) (SEQ ID NO: 69), z-DEVD-fmk (SEQ ID NO: 70), benzyloxycarbonyl-Asp(OCH₃)-Glu(OCH₃)-Val-Asp(OCH₃)--CH₂-fluoromethyl ketone (SEQ ID NO: 71), z-IETD-fmk (SEQ ID NO: 72), Z-VDVAD-fmk (SEQ ID NO: 73), CrmA, Bcl-2, Diap1, cIAP1, cIAP2, XIAP and p35.
3. (withdrawn) The pharmaceutical composition according to claim 1, wherein the caspase inhibitor is a di, tri, tetra or pentapeptide covalently bound to chloromethylketone.

4. (withdrawn – previously presented) The pharmaceutical composition according to claim 3, wherein the caspase inhibitor is Ac-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK) (SEQ ID NO: 69).
5. (withdrawn) The pharmaceutical composition according to claim 1, wherein the compound of the formula R-Lys-X is selected from the group wherein X represents a hydroxyl group, an amino group, a monoalkyl or dialkylamino group, an alkoxy group, an amino acid, an oligopeptide with 1-10 amino acids and wherein R is selected from the group comprising hydrogen, acyl group, acetyl group, an amino acid or a peptide with 2-70 amino acids.
6. (withdrawn) The pharmaceutical composition according to claim 5, wherein R represents a peptide having 8-12 amino acids.
7. (withdrawn – previously presented) The pharmaceutical composition according to claim 5, wherein R represents a peptide comprising the tetrapeptide His-Phe-Arg-Trp (SEQ ID NO: 74).
8. (withdrawn) The pharmaceutical composition according to claim 5, wherein R represents a peptide comprising the tripeptide Phe-Arg-Trp.
9. (withdrawn) The pharmaceutical composition according to claim 5, wherein R represents a peptide comprising the tripeptide His-Phe-Arg.
10. (withdrawn) The pharmaceutical composition according to claim 5, wherein R represents a peptide comprising at least one amino acid having D configuration.
11. (withdrawn) The pharmaceutical composition according to claim 5, wherein R represents a peptide consisting of amino acids having D configuration.

12. (withdrawn) The pharmaceutical composition according to claim 5, wherein R represents a peptide bearing an acyl group or acetyl group at the N-terminal end.
13. (withdrawn) The pharmaceutical composition according to claim 5, Wherein X represents an oligopeptide selected from the group comprising Pro, Pro-Thr, Pro-Val, Pro-Ala, Pro-Arg, Pro-Asn, Pro-Asp, Pro-Cys, Pro-Glu, Pro-Gln, Pro-Gly, Pro-His, Pro-Ile, Pro-Leu, Pro-Lys, Pro-Met, Pro-Phe, Pro-Pro, Pro-Ser, Pro-Trp, Pro-Thr-Thr, Pro-Thr-Val, Pro-Thr-Ala, Pro-Thr-Arg, Pro-Thr-Asn, Pro-Thr-Asp, Pro-Thr-Cys, Pro-Thr-Glu, Pro-Thr-Gln, Pro-Thr-Gly, Pro-Thr-His, Pro-Thr-Ile, Pro-Thr-Leu, Pro-Thr-Lys, Pro-Thr-Met, Pro-Thr-Phe, Pro-Thr-Pro, Pro-Thr-Ser, Pro-Thr-Trp, Pro-Val-Thr, Pro-Val-Val, Pro-Val-Ala, Pro-Val-Arg, Pro-Val-Asn, Pro-Val-Asp, Pro-Val-Cys, Pro-Val-Glu, Pro-Val-Gln, Pro-Val-Gly, Pro-Val-His, Pro-Val-Ile, Pro-Val-Leu, Pro-Val-Lys, Pro-Val-Met, Pro-Val-Phe, Pro-Val-Pro, Pro-Val-Ser, and Pro-Val-Trp.
14. (withdrawn) The pharmaceutical composition according to claim 13, wherein X represents an oligopeptide selected from the group comprising Pro, Pro-Thr or Pro-Val.
15. (withdrawn) The pharmaceutical composition according to claim 5, wherein X represents an oligopeptide bearing an amino group, a monoalkyl or dialkylamino group, an alkoxy group, a fluoromethyl ketone or a chloromethyl-ketone at the C-terminal end.
16. (withdrawn) The pharmaceutical composition according to claim 5, wherein X represents an oligopeptide comprising at least one amino acid having D configuration.
17. (withdrawn – previously presented) The pharmaceutical composition according to claim 5, wherein the compound of formula R-Lys-X is peptide of SEQ ID NO: 64.
18. (withdrawn – previously presented) The pharmaceutical composition according to claim 17, wherein at least one amino acid of SEQ ID NO: 64 has D-configuration.

19. (withdrawn) The pharmaceutical composition according to claim 5, wherein the compound of general formula R-Lys-X is a compound derived from the family of POMC-peptides which have anti-inflammatory and antiimmunosuppressive properties.

20. (withdrawn) The pharmaceutical composition according to claim 19, wherein the compound derived from the family of POMC-peptides is alpha-, beta- or gamma-MSH, ACTH, LPH or CLIP or protected, acylated, acetylated derivatives of said compounds.

21. (withdrawn) The pharmaceutical composition according to claim 5, further comprising at least one anti-inflammatory, anti-proliferic, anti-thrombotic, and/or anti-coagulative agent.

22. (currently amended) A method for the preparation of a hemocompatibly coated ~~medical-product~~ stent, comprising the steps of:

a) providing a surface of a ~~medical-product~~ stent,

b) coating said surface with a coating composition comprising ~~at least one caspase inhibitor and/or~~ at least one compound of formula R-Lys-X, wherein X represents a hydroxyl group, an amino group, a monoalkyl or dialkylamino group, an alkoxy group, an amino acid, an oligopeptide selected from the group comprising Pro, Pro-Thr, Pro-Val, Pro-Ala, Pro-Arg, Pro-Asn, Pro-Asp, Pro-Cys, Pro-Glu, Pro-Gln, Pro-Gly, Pro-His, Pro-Ile, Pro-Leu, Pro-Lys, Pro-Met, Pro-Phe, Pro-Pro, Pro-Ser, Pro-Trp, Pro-Thr-Thr, Pro-Thr-Val, Pro-Thr-Ala, Pro-Thr-Arg, Pro-Thr-Asn, Pro-Thr-Asp, Pro-Thr-Cys, Pro-Thr-Glu, Pro-Thr-Gln, Pro-Thr-Gly, Pro-Thr-His, Pro-Thr-Ile, Pro-Thr-Leu, Pro-Thr-Lys, Pro-Thr-Met, Pro-Thr-Phe, Pro-Thr-Pro, Pro-Thr-Ser, Pro-Thr-Trp, Pro-Val-Thr, Pro-Val-Val, Pro-Val-Ala, Pro-Val-Arg, Pro-Val-Asn, Pro-Val-Asp, Pro-Val-Cys, Pro-Val-Glu, Pro-Val-Gln, Pro-Val-Gly, Pro-Val-His, Pro-Val-Ile, Pro-Val-Leu, Pro-Val-Lys, Pro-Val-Met, Pro-Val-Phe, Pro-Val-Pro, Pro-Val-Ser, and Pro-Val-Trp and wherein R is selected from the group comprising hydrogen, acyl group, acetyl group, an amino acid or a peptide with 2 – 70 amino acids.

23. (currently amended) The method for the preparation of a hemocompatibly coated ~~medical product~~ stent according to claim 22, further comprising the step c):

c) coating said ~~caspase inhibitor and/or~~ compound of general formula R-Lys-X containing layer with a layer comprising ~~biologically stable and/or~~ biodegradable polymers.

24. (currently amended) A method for the preparation of a hemocompatibly coated ~~medical product~~ stent, comprising the steps of:

a) providing a surface of a ~~medical product~~ stent,

b') coating said surface with a first layer comprising ~~biologically stable and/or~~ biodegradable polymers and

b'') coating said first layer with a coating composition comprising ~~at least one caspase inhibitor and/or~~ at least one compound of formula R-Lys-X.

25. (currently amended) The method for the preparation of a hemocompatibly coated ~~medical product~~ stent according to claim 24, further comprising the step c):

c) coating said ~~caspase inhibitor and/or~~ compound of general formula R-Lys-X containing layer with a layer comprising ~~biologically stable and/or~~ biodegradable polymers.

26. (currently amended) The method according to any one of claims 22-25, wherein the layer of ~~biologically stable and/or~~ biodegradable polymers and/or the layer containing said ~~caspase inhibitor and/or~~ said compound of general formula R-Lys-X further comprises an anti-inflammatory, anti-proliferic, anti-thrombotic, and/or anti-coagulative agent.

27. (canceled)

28. (canceled)

29. (currently amended) A coated medical product stent obtained according to the method of any one of claims 22-25.

30. (canceled)